H.C. Wainwright raised the firm’s price target on Nuvation Bio (NUVB) to $11 from $10 and keeps a Buy rating on the shares. The firm sees additional upside in taletrectinib.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB: